Clinical Trial

PEP and O-PEP Device for Nebulization in Cystic Fibrosis

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 9, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Physiotherapy is an essential element in the comprehensive treatment of patients with cystic fibrosis. In symptomatic individuals, from a respiratory system perspective, it should be performed regularly, as it directly contributes to slowing disease progression. Even though patients perform airway-clearing physical therapy daily, it should be intensified during exacerbations. Although solutions for effectively clearing the airways have been sought for many years, there is still no leading technique for removing secretions from the respiratory tract. Modifications during inhalation aimed at thinning and loosening the accumulated thick mucus can facilitate the effective mobilization and expectoration of secretions, thus improving patients' quality of life.
Trial Details
NCT Number NCT06964074
Lead Sponsor National Institute for Tuberculosis and Lung Diseases, Poland
Conditions Cystic Fibrosis
Enrollment 70 participants
Start Date 2022-01-01
Primary Completion 2025-12-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-09